ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
The Impact of Sarcopenic Obesity on Weight Loss Outcomes and Recurrent Weight Gain Following Laparoscopic Sleeve Gastrectomy.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Subphenotyping Obesity in Pursuit of Personalized Medicine: The Devil is in the Details.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenic obesity (SO) presents a significant public health challenge. Although the prevalence of SO is on the rise, there is a notable paucity of research examining the impact of SO on weight loss efficacy following laparoscopic sleeve gastrectomy (LSG). Purpose: To investigate the impact of SO on weight loss outcomes and recurrent weight gain following LSG. Methods: We retrospectively gathered clinical data of 104 patients with obesity who underwent LSG in our hospital between January 2020 and September 2023. The ratio of fat mass to lean mass ≥0.8 was calculated for SO. Among them, the SO group (n=34) and the non-sarcopenic obesity (NSO) group (n=70), and the effect of SO on weight loss outcomes and recurrent weight gain were comparatively analyzed. Results: Within one year after LSG, SO patients had an apparently higher average body mass index, excess body mass index, and lower average percentage of excess weight loss than NSO patients (P<0.05). Furthermore, NSO patients had a statistically striking optimal weight loss rate more than SO patients in the first year after surgery (58.6% vs 35.3%, P=0.026). Within two years after LSG, SO patients had a lower occurrence rate of recurrent weight gain than NSO patients. Nonetheless, this difference was not statistically significant (P=0.212). Additionally, diabetes was an independent risk factor for recurrent weight gain postoperatively in patients with obesity when both univariate and multivariate analyses were conducted (P<0.05). Conclusion: SO adversely affects short-term weight loss outcomes after LSG. However, the effect of SO on postoperative recurrent weight gain was not statistically significant, indicating that further research is needed. Furthermore, diabetes is an independent risk factor for postoperative recurrent weight gain in patients with obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.